The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription
Myc oncoproteins exert tumorigenic effects by regulating expression of target oncogenes. Histone H3 lysine 79 (H3K79) methylation at Myc-responsive elements of target gene promoters is a strict prerequisite for Myc-induced transcriptional activation, and DOT1L is the only known histone methyltransfe...
Saved in:
Published in | Cancer research (Chicago, Ill.) Vol. 77; no. 9; pp. 2522 - 2533 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Association for Cancer Research, Inc
01.05.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Myc oncoproteins exert tumorigenic effects by regulating expression of target oncogenes. Histone H3 lysine 79 (H3K79) methylation at Myc-responsive elements of target gene promoters is a strict prerequisite for Myc-induced transcriptional activation, and DOT1L is the only known histone methyltransferase that catalyzes H3K79 methylation. Here, we show that N-Myc upregulates DOT1L mRNA and protein expression by binding to the DOT1L gene promoter. shRNA-mediated depletion of DOT1L reduced mRNA and protein expression of N-Myc target genes ODC1 and E2F2. DOT1L bound to the Myc Box II domain of N-Myc protein, and knockdown of DOT1L reduced histone H3K79 methylation and N-Myc protein binding at the ODC1 and E2F2 gene promoters and reduced neuroblastoma cell proliferation. Treatment with the small-molecule DOT1L inhibitor SGC0946 reduced H3K79 methylation and proliferation of MYCN gene–amplified neuroblastoma cells. In mice xenografts of neuroblastoma cells stably expressing doxycycline-inducible DOT1L shRNA, ablating DOT1L expression with doxycycline significantly reduced ODC1 and E2F2 expression, reduced tumor progression, and improved overall survival. In addition, high levels of DOT1L gene expression in human neuroblastoma tissues correlated with high levels of MYCN, ODC1, and E2F2 gene expression and independently correlated with poor patient survival. Taken together, our results identify DOT1L as a novel cofactor in N-Myc–mediated transcriptional activation of target genes and neuroblastoma oncogenesis. Furthermore, they characterize DOT1L inhibitors as novel anticancer agents against MYCN-amplified neuroblastoma. Cancer Res; 77(9); 2522–33. ©2017 AACR. |
---|---|
AbstractList | These findings offer a preclinical proof of concept for the use of DOT1L inhibitors as a strategy to disrupt the function of amplified N-MYC in neuroblastoma, a deadly type of pediatric cancer.Myc oncoproteins exert tumorigenic effects by regulating expression of target oncogenes. Histone H3 lysine 79 (H3K79) methylation at Myc-responsive elements of target gene promoters is a strict prerequisite for Myc-induced transcriptional activation, and DOT1L is the only known histone methyltransferase that catalyzes H3K79 methylation. Here, we show that N-Myc upregulates DOT1L mRNA and protein expression by binding to the DOT1L gene promoter. shRNA-mediated depletion of DOT1L reduced mRNA and protein expression of N-Myc target genes ODC1 and E2F2. DOT1L bound to the Myc Box II domain of N-Myc protein, and knockdown of DOT1L reduced histone H3K79 methylation and N-Myc protein binding at the ODC1 and E2F2 gene promoters and reduced neuroblastoma cell proliferation. Treatment with the small-molecule DOT1L inhibitor SGC0946 reduced H3K79 methylation and proliferation of MYCN gene–amplified neuroblastoma cells. In mice xenografts of neuroblastoma cells stably expressing doxycycline-inducible DOT1L shRNA, ablating DOT1L expression with doxycycline significantly reduced ODC1 and E2F2 expression, reduced tumor progression, and improved overall survival. In addition, high levels of DOT1L gene expression in human neuroblastoma tissues correlated with high levels of MYCN, ODC1, and E2F2 gene expression and independently correlated with poor patient survival. Taken together, our results identify DOT1L as a novel cofactor in N-Myc–mediated transcriptional activation of target genes and neuroblastoma oncogenesis. Furthermore, they characterize DOT1L inhibitors as novel anticancer agents against MYCN-amplified neuroblastoma. Cancer Res; 77(9); 2522–33. ©2017 AACR. These findings offer a preclinical proof of concept for the use of DOT1L inhibitors as a strategy to disrupt the function of amplified N-MYC in neuroblastoma, a deadly type of pediatric cancer. Myc oncoproteins exert tumorigenic effects by regulating expression of target oncogenes. Histone H3 lysine 79 (H3K79) methylation at Myc-responsive elements of target gene promoters is a strict prerequisite for Myc-induced transcriptional activation, and DOT1L is the only known histone methyltransferase that catalyzes H3K79 methylation. Here, we show that N-Myc upregulates DOT1L mRNA and protein expression by binding to the DOT1L gene promoter. shRNA-mediated depletion of DOT1L reduced mRNA and protein expression of N-Myc target genes ODC1 and E2F2. DOT1L bound to the Myc Box II domain of N-Myc protein, and knockdown of DOT1L reduced histone H3K79 methylation and N-Myc protein binding at the ODC1 and E2F2 gene promoters and reduced neuroblastoma cell proliferation. Treatment with the small-molecule DOT1L inhibitor SGC0946 reduced H3K79 methylation and proliferation of MYCN gene-amplified neuroblastoma cells. In mice xenografts of neuroblastoma cells stably expressing doxycycline-inducible DOT1L shRNA, ablating DOT1L expression with doxycycline significantly reduced ODC1 and E2F2 expression, reduced tumor progression, and improved overall survival. In addition, high levels of DOT1L gene expression in human neuroblastoma tissues correlated with high levels of MYCN, ODC1, and E2F2 gene expression and independently correlated with poor patient survival. Taken together, our results identify DOT1L as a novel cofactor in N-Myc-mediated transcriptional activation of target genes and neuroblastoma oncogenesis. Furthermore, they characterize DOT1L inhibitors as novel anticancer agents against MYCN-amplified neuroblastoma. Cancer Res; 77(9); 2522-33. [copy2017 AACR. Myc oncoproteins exert tumorigenic effects by regulating expression of target oncogenes. Histone H3 lysine 79 (H3K79) methylation at Myc-responsive elements of target gene promoters is a strict prerequisite for Myc-induced transcriptional activation, and DOT1L is the only known histone methyltransferase that catalyzes H3K79 methylation. Here, we show that N-Myc upregulates DOT1L mRNA and protein expression by binding to the DOT1L gene promoter. shRNA-mediated depletion of DOT1L reduced mRNA and protein expression of N-Myc target genes and DOT1L bound to the Myc Box II domain of N-Myc protein, and knockdown of DOT1L reduced histone H3K79 methylation and N-Myc protein binding at the ODC1 and E2F2 gene promoters and reduced neuroblastoma cell proliferation. Treatment with the small-molecule DOT1L inhibitor SGC0946 reduced H3K79 methylation and proliferation of gene-amplified neuroblastoma cells. In mice xenografts of neuroblastoma cells stably expressing doxycycline-inducible DOT1L shRNA, ablating DOT1L expression with doxycycline significantly reduced ODC1 and E2F2 expression, reduced tumor progression, and improved overall survival. In addition, high levels of DOT1L gene expression in human neuroblastoma tissues correlated with high levels of , and gene expression and independently correlated with poor patient survival. Taken together, our results identify DOT1L as a novel cofactor in N-Myc-mediated transcriptional activation of target genes and neuroblastoma oncogenesis. Furthermore, they characterize DOT1L inhibitors as novel anticancer agents against MYCN-amplified neuroblastoma. . Myc oncoproteins exert tumorigenic effects by regulating expression of target oncogenes. Histone H3 lysine 79 (H3K79) methylation at Myc-responsive elements of target gene promoters is a strict prerequisite for Myc-induced transcriptional activation, and DOT1L is the only known histone methyltransferase that catalyzes H3K79 methylation. Here, we show that N-Myc upregulates DOT1L mRNA and protein expression by binding to the DOT1L gene promoter. shRNA-mediated depletion of DOT1L reduced mRNA and protein expression of N-Myc target genes ODC1 and E2F2. DOT1L bound to the Myc Box II domain of N-Myc protein, and knockdown of DOT1L reduced histone H3K79 methylation and N-Myc protein binding at the ODC1 and E2F2 gene promoters and reduced neuroblastoma cell proliferation. Treatment with the small-molecule DOT1L inhibitor SGC0946 reduced H3K79 methylation and proliferation of MYCN gene–amplified neuroblastoma cells. In mice xenografts of neuroblastoma cells stably expressing doxycycline-inducible DOT1L shRNA, ablating DOT1L expression with doxycycline significantly reduced ODC1 and E2F2 expression, reduced tumor progression, and improved overall survival. In addition, high levels of DOT1L gene expression in human neuroblastoma tissues correlated with high levels of MYCN, ODC1, and E2F2 gene expression and independently correlated with poor patient survival. Taken together, our results identify DOT1L as a novel cofactor in N-Myc–mediated transcriptional activation of target genes and neuroblastoma oncogenesis. Furthermore, they characterize DOT1L inhibitors as novel anticancer agents against MYCN-amplified neuroblastoma. Cancer Res; 77(9); 2522–33. ©2017 AACR. |
Author | Milazzo, Giorgio Perini, Giovanni Tee, Andrew E.L. Wong, Matthew Hüttelmaier, Stefan Liu, Pei Yan Scarlett, Christopher J. Zhang, Xu Dong Jing, Duohui Polly, Patsie Bell, Jessica L. Poulos, Rebecca C. Atmadibrata, Bernard Sun, Yuting Wong, Jason W.H. Wang, Jenny Liu, Tao Ho, Nicholas Ling, Dora |
Author_xml | – sequence: 1 givenname: Matthew surname: Wong fullname: Wong, Matthew – sequence: 2 givenname: Andrew E.L. surname: Tee fullname: Tee, Andrew E.L. – sequence: 3 givenname: Giorgio surname: Milazzo fullname: Milazzo, Giorgio – sequence: 4 givenname: Jessica L. surname: Bell fullname: Bell, Jessica L. – sequence: 5 givenname: Rebecca C. surname: Poulos fullname: Poulos, Rebecca C. – sequence: 6 givenname: Bernard surname: Atmadibrata fullname: Atmadibrata, Bernard – sequence: 7 givenname: Yuting surname: Sun fullname: Sun, Yuting – sequence: 8 givenname: Duohui surname: Jing fullname: Jing, Duohui – sequence: 9 givenname: Nicholas surname: Ho fullname: Ho, Nicholas – sequence: 10 givenname: Dora surname: Ling fullname: Ling, Dora – sequence: 11 givenname: Pei Yan surname: Liu fullname: Liu, Pei Yan – sequence: 12 givenname: Xu Dong surname: Zhang fullname: Zhang, Xu Dong – sequence: 13 givenname: Stefan surname: Hüttelmaier fullname: Hüttelmaier, Stefan – sequence: 14 givenname: Jason W.H. surname: Wong fullname: Wong, Jason W.H. – sequence: 15 givenname: Jenny surname: Wang fullname: Wang, Jenny – sequence: 16 givenname: Patsie surname: Polly fullname: Polly, Patsie – sequence: 17 givenname: Giovanni surname: Perini fullname: Perini, Giovanni – sequence: 18 givenname: Christopher J. surname: Scarlett fullname: Scarlett, Christopher J. – sequence: 19 givenname: Tao surname: Liu fullname: Liu, Tao |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28209620$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc1LwzAYxoMouk3_BKXgxUtn0iZNiieZugnzA5knDyFN32qlbWaSHvbfm7LpwYMQeAn8nuf9eMZovzMdIHRK8JQQJi4xxiJmlCfT2fVjTLLwsnQPjQhLRcwpZfto9MscobFzn-HLCGaH6CgRCc6zBI_Q2-oDokXtfHCPHsB_bBpvVecqsMpBdPO0Isvo2ZrWeHDRI_TWFI0KeKuiYhO9wHvfKF9379EcgsNq0Gpbr31tumN0UKnGwcmuTtDr3e1qtoiXT_P72fUy1lSkPuZFkXGAiiWcYU5ZGsYsy0IoUYqCsrxMGaGCFGWaZZjnmrMkgVxrzXJVVoqmE3Sx9V1b89WD87KtnYamUR2Y3kmSY8JpTigO6Pkf9NP0tgvTBUqkCcOYk0Cd7ai-aKGUa1u3ym7kz9kCcLUFtDXOWaikrr0adg7HqxtJsBxCkkMAcghAhpAkyeQQUlCzP-qfBv_rvgEjEZQc |
CitedBy_id | crossref_primary_10_1016_j_bbcan_2022_188805 crossref_primary_10_18632_oncotarget_26416 crossref_primary_10_1007_s10555_020_09946_y crossref_primary_10_1089_omi_2018_0206 crossref_primary_10_3390_diseases9040078 crossref_primary_10_3390_ijms20010131 crossref_primary_10_1007_s00441_017_2773_y crossref_primary_10_3389_fonc_2019_01361 crossref_primary_10_1016_j_molcel_2019_06_034 crossref_primary_10_1002_cam4_70082 crossref_primary_10_1158_0008_5472_CAN_24_3304 crossref_primary_10_3389_fendo_2023_1085605 crossref_primary_10_1002_ijc_32936 crossref_primary_10_1126_sciadv_aav5590 crossref_primary_10_1016_j_jpha_2022_11_008 crossref_primary_10_1016_j_celrep_2021_109739 crossref_primary_10_1155_2021_6612689 crossref_primary_10_1038_s41467_019_12971_3 crossref_primary_10_1016_j_it_2021_03_006 crossref_primary_10_1038_s41423_018_0170_4 crossref_primary_10_18632_oncotarget_25084 crossref_primary_10_1126_scitranslmed_aao4680 crossref_primary_10_1016_j_canlet_2024_217263 crossref_primary_10_1007_s40495_018_0130_9 crossref_primary_10_2485_jhtb_31_101 crossref_primary_10_1158_1078_0432_CCR_21_1299 crossref_primary_10_1186_s13148_019_0778_y crossref_primary_10_1016_j_bbagrm_2022_194840 crossref_primary_10_1038_s41392_020_00323_3 crossref_primary_10_1038_s41419_019_2201_1 crossref_primary_10_1038_s41467_019_11132_w crossref_primary_10_1158_2159_8290_CD_21_0646 crossref_primary_10_1002_hep_31141 crossref_primary_10_1038_s41467_020_18013_7 crossref_primary_10_1186_s13058_022_01547_7 crossref_primary_10_3390_ijms242317085 crossref_primary_10_1073_pnas_1920372117 crossref_primary_10_1002_cnr2_2150 crossref_primary_10_1261_rna_070292_119 crossref_primary_10_3390_biom13010061 crossref_primary_10_1039_D1CB00016K crossref_primary_10_1111_jcmm_13644 crossref_primary_10_15252_embr_202051184 crossref_primary_10_1038_s41392_024_02039_0 crossref_primary_10_3389_fcell_2021_727353 crossref_primary_10_1038_s41388_022_02428_1 crossref_primary_10_2174_0113816128272203231121034814 crossref_primary_10_1186_s12964_024_01895_1 |
Cites_doi | 10.1016/S0960-9822(02)00901-6 10.1016/0959-8049(95)00015-B 10.1016/j.ejca.2009.03.002 10.1038/nrc1014 10.1016/j.cell.2007.05.009 10.1158/1078-0432.CCR-15-1666 10.1182/blood-2013-04-497644 10.1101/gad.2057811 10.1038/tpj.2010.53 10.1083/jcb.108.3.1093 10.1371/journal.pone.0003650 10.1093/hmg/10.7.699 10.1038/nature10910 10.1038/sj.onc.1208699 10.1093/emboj/19.21.5813 10.1200/JCO.1999.17.7.2264 10.1101/gad.1198204 10.1093/jnci/dju113 10.1083/jcb.107.4.1325 10.1182/blood-2011-02-334359 10.1038/sj.onc.1210661 10.1038/ncomms8821 10.1073/pnas.0806213105 10.1016/S1097-2765(01)00275-1 10.1200/JCO.2008.16.0630 10.1056/NEJMra0804577 10.1158/0008-5472.CAN-07-6866 10.1016/j.molcel.2015.02.028 10.1038/ncb1434 10.1158/0008-5472.CAN-10-2386 10.1038/nm.3832 10.1101/gad.1712408 10.1038/cddis.2013.84 10.1038/ncomms2304 10.1158/0008-5472.CAN-15-0423 10.1016/S0092-8674(03)00114-4 10.1016/j.ccr.2011.06.009 10.1038/nature10953 10.1007/978-1-4612-4380-9_25 10.1016/j.molcel.2005.05.009 |
ContentType | Journal Article |
Copyright | 2017 American Association for Cancer Research. Copyright American Association for Cancer Research, Inc. May 1, 2017 |
Copyright_xml | – notice: 2017 American Association for Cancer Research. – notice: Copyright American Association for Cancer Research, Inc. May 1, 2017 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7TM 7TO 7U9 8FD FR3 H94 P64 RC3 |
DOI | 10.1158/0008-5472.CAN-16-1663 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts Biotechnology and BioEngineering Abstracts Genetics Abstracts |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Genetics Abstracts Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts Technology Research Database Nucleic Acids Abstracts AIDS and Cancer Research Abstracts Immunology Abstracts Engineering Research Database Biotechnology and BioEngineering Abstracts |
DatabaseTitleList | Genetics Abstracts Genetics Abstracts MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1538-7445 |
EndPage | 2533 |
ExternalDocumentID | 28209620 10_1158_0008_5472_CAN_16_1663 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -ET 18M 29B 2WC 34G 39C 53G 5GY 5RE 5VS 6J9 AAFWJ AAJMC AAYXX ABOCM ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW ADNWM AENEX AETEA AFHIN AFOSN AFRAH AFUMD ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CITATION CS3 DIK DU5 EBS EJD F5P FRP GX1 H13 IH2 KQ8 L7B LSO OK1 P0W P2P PQQKQ RCR RHI RNS SJN TR2 W2D W8F WH7 WOQ YKV YZZ CGR CUY CVF ECM EIF NPM RHF 7T5 7TM 7TO 7U9 8FD FR3 H94 P64 RC3 |
ID | FETCH-LOGICAL-c483t-7bb67eef527507453005ddb8a8d8b459d351481bd366079c7522e9ccc59adfa43 |
ISSN | 0008-5472 |
IngestDate | Mon Jul 21 11:06:16 EDT 2025 Fri Jul 25 19:59:50 EDT 2025 Wed Feb 19 02:40:22 EST 2025 Thu Apr 24 22:58:22 EDT 2025 Tue Jul 01 01:12:29 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Language | English |
License | 2017 American Association for Cancer Research. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c483t-7bb67eef527507453005ddb8a8d8b459d351481bd366079c7522e9ccc59adfa43 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://cancerres.aacrjournals.org/content/canres/77/9/2522.full.pdf |
PMID | 28209620 |
PQID | 1983250071 |
PQPubID | 105549 |
PageCount | 12 |
ParticipantIDs | proquest_miscellaneous_1901749140 proquest_journals_1983250071 pubmed_primary_28209620 crossref_citationtrail_10_1158_0008_5472_CAN_16_1663 crossref_primary_10_1158_0008_5472_CAN_16_1663 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2017-05-01 |
PublicationDateYYYYMMDD | 2017-05-01 |
PublicationDate_xml | – month: 05 year: 2017 text: 2017-05-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Baltimore |
PublicationTitle | Cancer research (Chicago, Ill.) |
PublicationTitleAlternate | Cancer Res |
PublicationYear | 2017 |
Publisher | American Association for Cancer Research, Inc |
Publisher_xml | – name: American Association for Cancer Research, Inc |
References | Nguyen (2022061706165727000_bib29) 2011; 25 Brodeur (2022061706165727000_bib1) 2003; 3 Martinato (2022061706165727000_bib11) 2008; 3 Eilers (2022061706165727000_bib9) 2008; 22 Molenaar (2022061706165727000_bib23) 2012; 483 Nevins (2022061706165727000_bib39) 2001; 10 Yu (2022061706165727000_bib35) 2012; 3 Barski (2022061706165727000_bib14) 2007; 129 Schubeler (2022061706165727000_bib16) 2004; 18 Thomas (2022061706165727000_bib37) 2015; 58 Liu (2022061706165727000_bib20) 2009; 45 Onder (2022061706165727000_bib22) 2012; 483 Shahbazi (2022061706165727000_bib19) 2016; 22 Chen (2022061706165727000_bib28) 2015; 21 Min (2022061706165727000_bib13) 2003; 112 Herold (2022061706165727000_bib21) 2008; 105 Oberthuer (2022061706165727000_bib25) 2010; 10 Beier (2022061706165727000_bib30) 2000; 19 Daigle (2022061706165727000_bib34) 2011; 20 Cho (2022061706165727000_bib38) 2015; 6 Kaplan (2022061706165727000_bib26) 1992 Matthay (2022061706165727000_bib2) 1995; 31a Feng (2022061706165727000_bib12) 2002; 12 Hogarty (2022061706165727000_bib31) 2008; 68 Hirvonen (2022061706165727000_bib7) 1989; 108 Leone (2022061706165727000_bib32) 2001; 8 Mugrauer (2022061706165727000_bib6) 1988; 107 Nguyen (2022061706165727000_bib17) 2011; 117 Daigle (2022061706165727000_bib33) 2013; 122 Janoueix-Lerosey (2022061706165727000_bib3) 2009; 27 Fujiwara (2022061706165727000_bib40) 2011; 71 Guccione (2022061706165727000_bib10) 2006; 8 Kocak (2022061706165727000_bib24) 2013; 4 Tomioka (2022061706165727000_bib5) 2008; 27 Morillon (2022061706165727000_bib15) 2005; 18 Zeisig (2022061706165727000_bib18) 2005; 24 Maris (2022061706165727000_bib4) 2010; 362 Maris (2022061706165727000_bib8) 1999; 17 Liu (2022061706165727000_bib27) 2014; 106 Sun (2022061706165727000_bib36) 2015; 75 |
References_xml | – volume: 12 start-page: 1052 year: 2002 ident: 2022061706165727000_bib12 article-title: Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain publication-title: Curr Biol doi: 10.1016/S0960-9822(02)00901-6 – volume: 31a start-page: 572 year: 1995 ident: 2022061706165727000_bib2 article-title: Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results publication-title: Eur J Cancer doi: 10.1016/0959-8049(95)00015-B – volume: 45 start-page: 1846 year: 2009 ident: 2022061706165727000_bib20 article-title: Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors publication-title: Eur J Cancer doi: 10.1016/j.ejca.2009.03.002 – volume: 3 start-page: 203 year: 2003 ident: 2022061706165727000_bib1 article-title: Neuroblastoma: biological insights into a clinical enigma publication-title: Nat Rev Cancer doi: 10.1038/nrc1014 – volume: 129 start-page: 823 year: 2007 ident: 2022061706165727000_bib14 article-title: High-resolution profiling of histone methylations in the human genome publication-title: Cell doi: 10.1016/j.cell.2007.05.009 – volume: 22 start-page: 2534 year: 2016 ident: 2022061706165727000_bib19 article-title: The bromodomain inhibitor JQ1 and the histone deacetylase inhibitor panobinostat synergistically reduce N-Myc expression and induce anticancer effects publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-15-1666 – volume: 122 start-page: 1017 year: 2013 ident: 2022061706165727000_bib33 article-title: Potent inhibition of DOT1L as treatment of MLL-fusion leukemia publication-title: Blood doi: 10.1182/blood-2013-04-497644 – volume: 25 start-page: 1345 year: 2011 ident: 2022061706165727000_bib29 article-title: The diverse functions of Dot1 and H3K79 methylation publication-title: Genes Dev doi: 10.1101/gad.2057811 – volume: 10 start-page: 258 year: 2010 ident: 2022061706165727000_bib25 article-title: Comparison of performance of one-color and two-color gene-expression analyses in predicting clinical endpoints of neuroblastoma patients publication-title: Pharmacogenomics J doi: 10.1038/tpj.2010.53 – volume: 108 start-page: 1093 year: 1989 ident: 2022061706165727000_bib7 article-title: The N-myc proto-oncogene and IGF-II growth factor mRNAs are expressed by distinct cells in human fetal kidney and brain publication-title: J Cell Biol doi: 10.1083/jcb.108.3.1093 – volume: 3 start-page: e3650 year: 2008 ident: 2022061706165727000_bib11 article-title: Analysis of Myc-induced histone modifications on target chromatin publication-title: PLoS One doi: 10.1371/journal.pone.0003650 – volume: 10 start-page: 699 year: 2001 ident: 2022061706165727000_bib39 article-title: The Rb/E2F pathway and cancer publication-title: Hum Mol Genet doi: 10.1093/hmg/10.7.699 – volume: 483 start-page: 589 year: 2012 ident: 2022061706165727000_bib23 article-title: Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes publication-title: Nature doi: 10.1038/nature10910 – volume: 24 start-page: 5525 year: 2005 ident: 2022061706165727000_bib18 article-title: The eleven-nineteen-leukemia protein ENL connects nuclear MLL fusion partners with chromatin publication-title: Oncogene doi: 10.1038/sj.onc.1208699 – volume: 19 start-page: 5813 year: 2000 ident: 2022061706165727000_bib30 article-title: Induction of cyclin E-cdk2 kinase activity, E2F-dependent transcription and cell growth by Myc are genetically separable events publication-title: EMBO J doi: 10.1093/emboj/19.21.5813 – volume: 17 start-page: 2264 year: 1999 ident: 2022061706165727000_bib8 article-title: Molecular biology of neuroblastoma publication-title: J Clin Oncol doi: 10.1200/JCO.1999.17.7.2264 – volume: 18 start-page: 1263 year: 2004 ident: 2022061706165727000_bib16 article-title: The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote publication-title: Genes Dev doi: 10.1101/gad.1198204 – volume: 106 start-page: dju113 year: 2014 ident: 2022061706165727000_bib27 article-title: Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression publication-title: J Natl Cancer Inst doi: 10.1093/jnci/dju113 – volume: 107 start-page: 1325 year: 1988 ident: 2022061706165727000_bib6 article-title: N-myc proto-oncogene expression during organogenesis in the developing mouse as revealed by in situ hybridization publication-title: J Cell Biol doi: 10.1083/jcb.107.4.1325 – volume: 117 start-page: 6912 year: 2011 ident: 2022061706165727000_bib17 article-title: DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis publication-title: Blood doi: 10.1182/blood-2011-02-334359 – volume: 27 start-page: 441 year: 2008 ident: 2022061706165727000_bib5 article-title: Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature publication-title: Oncogene doi: 10.1038/sj.onc.1210661 – volume: 6 start-page: 7821 year: 2015 ident: 2022061706165727000_bib38 article-title: DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression publication-title: Nat Commun doi: 10.1038/ncomms8821 – volume: 105 start-page: 18507 year: 2008 ident: 2022061706165727000_bib21 article-title: Inducible and reversible gene silencing by stable integration of an shRNA-encoding lentivirus in transgenic rats publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0806213105 – volume: 8 start-page: 105 year: 2001 ident: 2022061706165727000_bib32 article-title: Myc requires distinct E2F activities to induce S phase and apoptosis publication-title: Mol Cell doi: 10.1016/S1097-2765(01)00275-1 – volume: 27 start-page: 1026 year: 2009 ident: 2022061706165727000_bib3 article-title: Overall genomic pattern is a predictor of outcome in neuroblastoma publication-title: J Clin Oncol doi: 10.1200/JCO.2008.16.0630 – volume: 362 start-page: 2202 year: 2010 ident: 2022061706165727000_bib4 article-title: Recent advances in neuroblastoma publication-title: N Engl J Med doi: 10.1056/NEJMra0804577 – volume: 68 start-page: 9735 year: 2008 ident: 2022061706165727000_bib31 article-title: ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-07-6866 – volume: 58 start-page: 440 year: 2015 ident: 2022061706165727000_bib37 article-title: Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC publication-title: Mol Cell doi: 10.1016/j.molcel.2015.02.028 – volume: 8 start-page: 764 year: 2006 ident: 2022061706165727000_bib10 article-title: Myc-binding-site recognition in the human genome is determined by chromatin context publication-title: Nat Cell Biol doi: 10.1038/ncb1434 – volume: 71 start-page: 1924 year: 2011 ident: 2022061706165727000_bib40 article-title: Prediction and genetic demonstration of a role for activator E2Fs in Myc-induced tumors publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-10-2386 – volume: 21 start-page: 335 year: 2015 ident: 2022061706165727000_bib28 article-title: DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia publication-title: Nat Med doi: 10.1038/nm.3832 – volume: 22 start-page: 2755 year: 2008 ident: 2022061706165727000_bib9 article-title: Myc's broad reach publication-title: Genes Dev doi: 10.1101/gad.1712408 – volume: 4 start-page: e586 year: 2013 ident: 2022061706165727000_bib24 article-title: Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma publication-title: Cell Death Dis doi: 10.1038/cddis.2013.84 – volume: 3 start-page: 1288 year: 2012 ident: 2022061706165727000_bib35 article-title: Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors publication-title: Nat Commun doi: 10.1038/ncomms2304 – volume: 75 start-page: 5143 year: 2015 ident: 2022061706165727000_bib36 article-title: WDR5 supports an N-Myc transcriptional complex that drives a protumorigenic gene expression signature in neuroblastoma publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-15-0423 – volume: 112 start-page: 711 year: 2003 ident: 2022061706165727000_bib13 article-title: Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase publication-title: Cell doi: 10.1016/S0092-8674(03)00114-4 – volume: 20 start-page: 53 year: 2011 ident: 2022061706165727000_bib34 article-title: Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor publication-title: Cancer Cell doi: 10.1016/j.ccr.2011.06.009 – volume: 483 start-page: 598 year: 2012 ident: 2022061706165727000_bib22 article-title: Chromatin-modifying enzymes as modulators of reprogramming publication-title: Nature doi: 10.1038/nature10953 – start-page: 319 volume-title: Breakthroughs in Statistics. year: 1992 ident: 2022061706165727000_bib26 article-title: Nonparametric estimation from incomplete observations doi: 10.1007/978-1-4612-4380-9_25 – volume: 18 start-page: 723 year: 2005 ident: 2022061706165727000_bib15 article-title: Dynamic lysine methylation on histone H3 defines the regulatory phase of gene transcription publication-title: Mol Cell doi: 10.1016/j.molcel.2005.05.009 |
SSID | ssj0005105 |
Score | 2.4821823 |
Snippet | Myc oncoproteins exert tumorigenic effects by regulating expression of target oncogenes. Histone H3 lysine 79 (H3K79) methylation at Myc-responsive elements of... These findings offer a preclinical proof of concept for the use of DOT1L inhibitors as a strategy to disrupt the function of amplified N-MYC in neuroblastoma,... |
SourceID | proquest pubmed crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 2522 |
SubjectTerms | Animals Antitumor agents Cancer Cell Line, Tumor Cell proliferation Cell Proliferation - drug effects DNA methylation DNA Methylation - drug effects Doxycycline Enzyme Inhibitors - administration & dosage Gene expression Gene Expression Regulation, Neoplastic - drug effects Histone H3 Histone methyltransferase Histone-Lysine N-Methyltransferase - antagonists & inhibitors Histone-Lysine N-Methyltransferase - genetics Humans Lysine Methyltransferases - antagonists & inhibitors Methyltransferases - genetics Mice Myc protein MYCN gene N-Myc protein N-Myc Proto-Oncogene Protein - biosynthesis N-Myc Proto-Oncogene Protein - genetics Neuroblastoma Neuroblastoma - drug therapy Neuroblastoma - genetics Neuroblastoma - pathology Neuroblasts Promoter Regions, Genetic Promoters Protein expression Proteins Transcription activation Transcription, Genetic Tumorigenesis Xenografts |
Title | The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription |
URI | https://www.ncbi.nlm.nih.gov/pubmed/28209620 https://www.proquest.com/docview/1983250071 https://www.proquest.com/docview/1901749140 |
Volume | 77 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELdgSIgXxDcdAxmJtyolH3YSP06lYxptJ1AqVeIhih0HJoUOdekD_eu5s5200YYYSFVUpbFd-X45n8-_uyPknR9WHJYx7YlIKo-lvvJkgn6rUpew4OLRHMYOz-bx6YKdLflyRwky0SWNHKntjXEl_yNVuAdyxSjZf5Bs1yncgO8gX7iChOF6axmbPB9gKc40THndGDtUr2FtGn44z4IpRgKANDSqsw0Wjyng8R8FWp1fbBl644ECjWfznLdKZN9oHSMy1kOXF-i7Ofi1DA6jYep6tOdPaDm-rpB45xmwhB_LnxxOOpfz7KIutlvT0ceLy_U3Swvbjxw6Q6KuKlx4hHNQwKLX0QE7pZt6nCU9petqt1hwiX0Nym2csluNQ27zZFzX9Dy11Ejb92h8PPeCGD5OX_Yya8_P85PFdJpnk2V2l9wLYUuB1S4-fd5llueO7tp26KK9YJj3Nw7St2P-sDkxRkr2iDx0uwt6bKHymNzRqyfk_szxJ56Sr4AY6hBDryGGGsTQFjG0hxgqf9EdYigihvYQ84wsTibZ-NRz5TU8xdKo8RIp40TrimOK_4RxLFxQljIt0jKVjIsSgzxgV1NGcewnQiUgGS2UUlwUZVWw6Dk5WMHffUkomD8yjDRXItSsiispZFQynUSxKBRIcEBYO1m5crnnsQRKnZs9KE-RA5HmOMc5zHEexDnO8YCMumY_bfKVvzU4aiWRu_f0Kg8ErFocbekBedv9DFoUj8aKlb7c4DMAXCYC5g_ICyvBbsQQjGQRh_7hLVq_Ig92r8AROWjWG_0arNZGvjFw-w3L2pIW |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Histone+Methyltransferase+DOT1L+Promotes+Neuroblastoma+by+Regulating+Gene+Transcription&rft.jtitle=Cancer+research+%28Chicago%2C+Ill.%29&rft.au=Wong%2C+Matthew&rft.au=Tee%2C+Andrew+EL&rft.au=Milazzo%2C+Giorgio&rft.au=Bell%2C+Jessica+L&rft.date=2017-05-01&rft.issn=0008-5472&rft.volume=77&rft.issue=9&rft.spage=2522&rft.epage=2533&rft_id=info:doi/10.1158%2F0008-5472.CAN-16-1663&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-5472&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-5472&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-5472&client=summon |